[A23-37] Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2023
Project no.:
A23-37
Commission:
Commission awarded on 28.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor, anaplastic lymphoma kinase or c-ros oncogene 1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or who have metastatic NSCLC.
- Patients with PD-L1 expression in ≥ 50% of tumour cells: added benefit not proven
- Patients with PD-L1 expression in ≥ 1 % to < 50 % of tumour cells: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-36 | Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-98 | Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-60 | Cemiplimab - Benefit assessment according to §35a Social Code Book V | Commission completed |